[Hereditary aspects of pancreatitis]

Med Wieku Rozwoj. 2003 Jan-Mar;7(1):57-66.
[Article in Polish]

Abstract

Pancreatitis presents clinically as acute and chronic form. A common characteristic of these two forms is enzymatic autodigestion of pancreas in the course of the disease. It results from premature activation of pancreatic digestive enzymes and disturbance of subtle balance between proteolytic enzymes and their inhibitors. The way to understand the character of mechanisms leading to development of pancreatitis has been simplified by discovery of genetic factors, which are able to initiate pathological changes at tissue level. Mutations in the PRSS1 gene (first of all R122H and N29I mutations), which encodes for cationic trypsin, cause trypsin to be protected from autodegradation. These mutations also cause precursor of trypsin - trypsinogen, to be activated easier. On the other hand mutations in the SPINK1 gene have been identified. SPINK1 gene encodes for the most important protease inhibitor of the pancreatic fluid. The most frequent mutation, namely N34S, decrease SPINK1 protein in its activity. The link between the genotype and phenotype is not clear in every case. It is probable that pancreatitis will be recognized as poligenic with many genes engaged in the disease development. Pancreatic cancer is a frequent consequence of pancreatitis. It is a very invasive cancer with high mortality. In the course of pancreatic inflammation intensive cell proliferation takes place for regeneration of pancreas damage. It is the chance for amplification of pathological changes in DNA, which have arisen as a ROS's (Reactive Oxygen Species) and RNOS's (Reactive Nitrogen Oxide Species) action effect. ROS and RNOS are generated in the course of pancreas inflammation.

Publication types

  • English Abstract
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Genetic Predisposition to Disease
  • Humans
  • Pancreatic Neoplasms / genetics*
  • Pancreatic Neoplasms / physiopathology
  • Pancreatic Neoplasms / therapy
  • Pancreatitis / genetics*
  • Pancreatitis / physiopathology
  • Pancreatitis / therapy
  • Point Mutation
  • Risk Factors
  • Trypsin / genetics*
  • Trypsin Inhibitor, Kazal Pancreatic / genetics*
  • Trypsinogen / genetics*

Substances

  • Trypsin Inhibitor, Kazal Pancreatic
  • Trypsinogen
  • PRSS1 protein, human
  • Trypsin